← Back to patent-cliff list
Dexfenfluramine Hydrochloride
Tier C — Watch / tradeDexfenfluramine Hydrochloride
Laboratoires Servier
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SERT
Brand：Isolipan, Glypolix, Redux, Isomeride, Dipondal, Adifax
Indications (approved)：Solid tumour, Obesity
Regional status
US
Withdrawn
EU
Phase II
2020-10-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dexfenfluramine Hydrochloride?
Approved indications include: Solid tumour, Obesity.
When does the Dexfenfluramine Hydrochloride patent expire?
No public expiry year is available for Dexfenfluramine Hydrochloride yet; this page updates once verified.
How do I get a quote for Dexfenfluramine Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06